⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 6, 2024

Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors

Takafumi Koyama Kan Yonemori Toshio Shimizu Jun Sato Shunsuke Kondo Kazuki Sudo Tatsuya Yoshida Yuki Katsuya T. Imaizumi Masashi Enomoto Ryoko Seki Noboru Yamamoto

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Figure S1 shows the study design.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koyama et al. (2024) studied this question.

synapsesocial.com/papers/68e59329b6db64358752e70c https://doi.org/10.1158/2767-9764.26953778

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
2Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
3Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
4Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
5Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024

Figure 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors2024
Supplementary Figure S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer2024